EA200200396A1 - Фармацевтические композиции фибринолитического агента - Google Patents

Фармацевтические композиции фибринолитического агента

Info

Publication number
EA200200396A1
EA200200396A1 EA200200396A EA200200396A EA200200396A1 EA 200200396 A1 EA200200396 A1 EA 200200396A1 EA 200200396 A EA200200396 A EA 200200396A EA 200200396 A EA200200396 A EA 200200396A EA 200200396 A1 EA200200396 A1 EA 200200396A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical compositions
fibrinolytic agent
lyophilized
composition
fibrinolytic
Prior art date
Application number
EA200200396A
Other languages
English (en)
Other versions
EA004627B1 (ru
Inventor
Брент С. Кендрик
Брайан Петерсон
Original Assignee
Амген Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Амген Инк. filed Critical Амген Инк.
Publication of EA200200396A1 publication Critical patent/EA200200396A1/ru
Publication of EA004627B1 publication Critical patent/EA004627B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Описаны замороженная и лиофилизированная композиции металлопротеиназного фибринолитического агента (фибролазы или NAT), способ приготовления лиофилизированной композиции и набор и способ восстановления лиофилизированной композиции.Отчет о международном поиске был опубликован 2001.10.18.
EA200200396A 1999-10-01 2000-09-29 Фармацевтические композиции фибринолитического агента EA004627B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/411,335 US6440414B1 (en) 1999-10-01 1999-10-01 Pharmaceutical compositions of fibrinolytic agent
PCT/US2000/027022 WO2001024817A2 (en) 1999-10-01 2000-09-29 Pharmaceutical compositions of fibrinolytic agent

Publications (2)

Publication Number Publication Date
EA200200396A1 true EA200200396A1 (ru) 2002-10-31
EA004627B1 EA004627B1 (ru) 2004-06-24

Family

ID=23628514

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200200396A EA004627B1 (ru) 1999-10-01 2000-09-29 Фармацевтические композиции фибринолитического агента
EA200400182A EA006600B1 (ru) 1999-10-01 2000-09-29 Фармацевтические композиции фибринолитического агента

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA200400182A EA006600B1 (ru) 1999-10-01 2000-09-29 Фармацевтические композиции фибринолитического агента

Country Status (28)

Country Link
US (4) US6440414B1 (ru)
EP (2) EP1438967A3 (ru)
JP (1) JP2003510369A (ru)
KR (1) KR100717435B1 (ru)
CN (2) CN101209347A (ru)
AT (1) ATE262923T1 (ru)
AU (1) AU769313B2 (ru)
BG (1) BG106578A (ru)
BR (1) BR0014420A (ru)
CA (1) CA2385966A1 (ru)
CZ (1) CZ20021033A3 (ru)
DE (2) DE60009529T2 (ru)
DK (1) DK1220685T3 (ru)
EA (2) EA004627B1 (ru)
ES (2) ES2224917T1 (ru)
HK (1) HK1049112B (ru)
HU (1) HUP0202654A3 (ru)
IL (1) IL148842A0 (ru)
MX (1) MXPA02003197A (ru)
NO (1) NO20021500L (ru)
NZ (4) NZ540967A (ru)
PL (1) PL355016A1 (ru)
PT (1) PT1220685E (ru)
SG (1) SG148823A1 (ru)
SK (1) SK4242002A3 (ru)
WO (1) WO2001024817A2 (ru)
YU (1) YU23302A (ru)
ZA (1) ZA200202400B (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5149470B2 (ja) 1999-02-22 2013-02-20 バクスター・インターナショナル・インコーポレイテッド 新規のアルブミンを含有していない第ｖｉｉｉ因子処方物
US6261820B1 (en) 1999-10-01 2001-07-17 Amgen Inc. Fibronolytically active polypeptide
US6440414B1 (en) 1999-10-01 2002-08-27 Amgen Inc. Pharmaceutical compositions of fibrinolytic agent
US6455269B1 (en) * 1999-12-17 2002-09-24 Amgen, Inc. Method for localized administration of fibrinolytic metalloproteinases
US7033776B2 (en) 1999-12-17 2006-04-25 Amgen Inc. Method for treatment of indwelling catheter occlusion using fibrinolytic metalloproteinases
DE10149030A1 (de) * 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
US20050239746A1 (en) * 2002-02-01 2005-10-27 Penkler Lawrence J Pharmaceutical composition
WO2003068805A2 (en) * 2002-02-14 2003-08-21 Bayer Pharmaceuticals Corporation Formulation strategies in stabilizing peptides in organic solvents and in dried states
US6803046B2 (en) * 2002-08-16 2004-10-12 Bracco International B.V. Sincalide formulations
JP5201992B2 (ja) * 2004-12-15 2013-06-05 バイオビトラム・アクテイエボラーグ（パブリツク） ケラチノサイト増殖因子の治療用製剤
KR20080076907A (ko) * 2005-11-18 2008-08-20 에자이 알앤드디 매니지먼트 가부시키가이샤 신나미드 유도체의 제조 방법
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
KR100807692B1 (ko) * 2006-11-08 2008-02-28 신라대학교 산학협력단 혈전용해성 메탈로프로테아제 및 이를 포함하는 조성물
EP1958618A1 (de) 2007-02-15 2008-08-20 Octapharma AG Verfahren zur Gefriertrocknung mit optimierter Rekonstitution von Biopolymeren
CA2742328C (en) 2008-11-07 2019-02-26 Baxter International Inc. Factor viii formulations
KR20120050442A (ko) * 2009-07-10 2012-05-18 쓰롬보제닉스 엔.브이. 플라스미노겐 및 플라스민의 변이체
CN102000022A (zh) * 2010-11-23 2011-04-06 郑州大学 注射用重组双功能纤溶酶冻干制剂及其制备方法
CA2823491A1 (en) 2011-01-05 2012-07-12 Thrombogenics Nv Plasminogen and plasmin variants
US9644196B2 (en) 2011-08-12 2017-05-09 Thrombogenics Nv Plasminogen and plasmin variants
US20140212405A1 (en) 2013-01-28 2014-07-31 2294719 Ontario Limited Fibrinolytic/Proteolytic Treatment of Myofacial and Neuropathic Pain and Related Conditions
US11137409B2 (en) * 2014-11-06 2021-10-05 The Regents Of The University Of Colorado, A Body Corporate Identification of novel disease states using viscoelastic analysis in the presence of a thrombolytic agent
CN113382714A (zh) * 2019-01-06 2021-09-10 恩多全球美学有限公司 胶原酶制剂及其制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2310133A2 (fr) 1975-05-05 1976-12-03 Fabre Sa Pierre Nouveau medicament comportant un activateur du plasminogene perfectionne
JPS57500844A (ru) * 1980-06-27 1982-05-13
US4447236A (en) * 1982-02-05 1984-05-08 Cordis Corporation Infusion catheter system
US4610879A (en) 1984-01-06 1986-09-09 University Of Southern California Fibrinolytic enzyme from snake vernom
CA1237482A (en) * 1984-03-09 1988-05-31 Frank B. Stiles Catheter for effecting removal of obstructions from a biological duct
US4755167A (en) * 1984-04-10 1988-07-05 Research Corporation In vivo method for distribution and stirring of therapeutic agents
US4885242A (en) * 1984-10-30 1989-12-05 Phillips Petroleum Company Genes from pichia histidine pathway and uses thereof
US4855231A (en) * 1984-10-30 1989-08-08 Phillips Petroleum Company Regulatory region for heterologous gene expression in yeast
US4837148A (en) * 1984-10-30 1989-06-06 Phillips Petroleum Company Autonomous replication sequences for yeast strains of the genus pichia
US4818700A (en) * 1985-10-25 1989-04-04 Phillips Petroleum Company Pichia pastoris argininosuccinate lyase gene and uses thereof
US4812405A (en) * 1986-02-18 1989-03-14 Phillips Petroleum Company Double auxotrophic mutants of Pichia pastoris and methods for preparation
US5000185A (en) * 1986-02-28 1991-03-19 Cardiovascular Imaging Systems, Inc. Method for intravascular two-dimensional ultrasonography and recanalization
US4848700A (en) * 1987-04-16 1989-07-18 Lockheed John A Canard control system for aircraft
ZA889415B (en) 1987-12-18 1989-09-27 Chiron Corp Compositions and method for recombinant production of crotalidus venum fibrolase
WO1990007352A1 (en) 1989-01-04 1990-07-12 Boston Scientific Corporation Angioplasty catheter
US5222941A (en) * 1990-01-12 1993-06-29 Don Michael T Anthony Method of dissolving an obstruction in a vessel
ES2180528T3 (es) 1990-01-16 2003-02-16 Ct Ingenieria Genetica Biotech Metodo de expresion de genes heterologos en la levadura pichia pastoris, vectores de expresion y microorganismos transformados.
US5709676A (en) * 1990-02-14 1998-01-20 Alt; Eckhard Synergistic treatment of stenosed blood vessels using shock waves and dissolving medication
US5250034A (en) * 1990-09-17 1993-10-05 E-Z-Em, Inc. Pressure responsive valve catheter
US5167628A (en) * 1991-05-02 1992-12-01 Boyles Paul W Aortic balloon catheter assembly for indirect infusion of the coronary arteries
US5380273A (en) * 1992-05-19 1995-01-10 Dubrul; Will R. Vibrating catheter
EP0624642B1 (en) 1993-05-12 1999-01-20 Indian Council For Medical Research Novel thrombolytic agent, process for preparing same and its use for the preparation of a thrombi dissolving medicament
US5370653A (en) * 1993-07-22 1994-12-06 Micro Therapeutics, Inc. Thrombectomy method and apparatus
AU692497B2 (en) 1993-12-17 1998-06-11 Asahi Kasei Pharma Corporation Soluble thrombomodulin-containing pharmaceutical composition
US5626564A (en) * 1995-03-31 1997-05-06 Creighton University Adjustable sideholes catheter
US6020181A (en) * 1995-05-17 2000-02-01 New York Blood, Inc. Inhibition of thrombus formation by medical related apparatus comprising treating with fibrinolytic matrix metalloproteinase
US5830468A (en) * 1995-05-17 1998-11-03 The New York Blood Center, Inc. Fibrin(ogen) degradation by fibrinolytic matrix metalloproteinase
US5741779A (en) * 1996-05-10 1998-04-21 Xoma Corporation Antithrombotic materials and methods
WO1997045105A1 (en) 1996-05-24 1997-12-04 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing diseases of body passageways
US5951981A (en) 1996-12-02 1999-09-14 Diatide, Inc. Thrombolytic agents with antithrombotic activity
US6413760B1 (en) 1997-04-15 2002-07-02 Genetics Institute, Inc. Highly purified mocarhagin cobra venom protease polynucleotides endcoding same and related proteases and therapeutic uses thereof
US6261820B1 (en) 1999-10-01 2001-07-17 Amgen Inc. Fibronolytically active polypeptide
US6440414B1 (en) 1999-10-01 2002-08-27 Amgen Inc. Pharmaceutical compositions of fibrinolytic agent
US6455269B1 (en) * 1999-12-17 2002-09-24 Amgen, Inc. Method for localized administration of fibrinolytic metalloproteinases
US20020081685A1 (en) 2000-08-03 2002-06-27 Fox Brian A. Disintegrin homologs, ZSNK10, ZSNK11, and ZSNK12

Also Published As

Publication number Publication date
HUP0202654A3 (en) 2003-11-28
EP1220685A2 (en) 2002-07-10
EP1220685B1 (en) 2004-03-31
EP1438967A3 (en) 2005-01-26
ES2224917T1 (es) 2005-03-16
NZ518007A (en) 2004-03-26
JP2003510369A (ja) 2003-03-18
EA004627B1 (ru) 2004-06-24
CA2385966A1 (en) 2001-04-12
US20060246053A1 (en) 2006-11-02
CZ20021033A3 (cs) 2003-06-18
US6440414B1 (en) 2002-08-27
KR20020053065A (ko) 2002-07-04
HUP0202654A2 (hu) 2002-12-28
EA006600B1 (ru) 2006-02-24
AU769313B2 (en) 2004-01-22
HK1049112A1 (en) 2003-05-02
EA200400182A1 (ru) 2004-08-26
BG106578A (bg) 2003-04-30
CN100353999C (zh) 2007-12-12
HK1049112B (zh) 2005-01-21
ATE262923T1 (de) 2004-04-15
DE04007657T1 (de) 2005-01-13
AU7743000A (en) 2001-05-10
CN1402641A (zh) 2003-03-12
BR0014420A (pt) 2002-06-11
IL148842A0 (en) 2002-09-12
NO20021500D0 (no) 2002-03-26
US7244426B2 (en) 2007-07-17
NZ540967A (en) 2007-02-23
DE60009529D1 (de) 2004-05-06
SG148823A1 (en) 2009-01-29
US7138114B2 (en) 2006-11-21
ZA200202400B (en) 2003-05-28
DK1220685T3 (da) 2004-08-02
US7311908B2 (en) 2007-12-25
NZ530959A (en) 2005-08-26
US20020192207A1 (en) 2002-12-19
WO2001024817A2 (en) 2001-04-12
YU23302A (sh) 2005-06-10
US20060263347A1 (en) 2006-11-23
MXPA02003197A (es) 2002-09-30
EP1438967A2 (en) 2004-07-21
NZ550200A (en) 2008-04-30
DE60009529T2 (de) 2005-04-14
PT1220685E (pt) 2004-08-31
CN101209347A (zh) 2008-07-02
SK4242002A3 (en) 2003-08-05
WO2001024817A3 (en) 2001-10-18
NO20021500L (no) 2002-05-27
PL355016A1 (en) 2004-03-22
ES2218228T3 (es) 2004-11-16
KR100717435B1 (ko) 2007-05-14

Similar Documents

Publication Publication Date Title
EA200200396A1 (ru) Фармацевтические композиции фибринолитического агента
ES2131781T3 (es) Formulacion estable liofilizada que comprende una proteina, equipo de dosificacion.
EA200200479A1 (ru) Новые олигосахариды, их получение и содержащие их фармацевтические композиции
EA200100838A1 (ru) Конъюгаты гксф
EA200000920A1 (ru) Производные бициклических гидроксамовых кислот
AR013499A1 (es) Composiciones solidas que comprenden un polipeptido ciclosporina y un surfactante anionico
BR9713866A (pt) Composição farmacéutica
EA199900749A1 (ru) Фармацевтическая композиция
ES2175940T3 (es) Formulacion farmaceutica de un compuesto didemnina.
RS49723B (sr) Farmaceutska kompozicija koja sadrži entakapon ili nitekapon kao i umreženi derivat celuloze
DE60019100D1 (de) Im wesentlichen ölfreie cyclosporin zusammensetzungen
FI915093A0 (fi) Sackarinderivat anvaendbara som inhibitorer foer proteolytiskt enzym och deras framstaellning.
SE0102843L (sv) Stabiliserad oral farmaceutisk komposition innehållande jodid och jodat och metod
AR034226A2 (es) Procedimiento perfeccionado para estabilizar proteinas.
MY121982A (en) Pharmaceutical compositions for freeze drying
PL328916A1 (en) Compositions containing inhibitors of hiv protease, such as vx 478 and water-soluble vitamin e compound such as vitamin e-tpgs
EA200100984A1 (ru) Новые кристаллические формы макролидного антибиотика
EA200001050A1 (ru) Малеат пароксетина
AU7028798A (en) Use of 2-methylthiazolidine-2,4-dicarboxylic acid as mucolytic agent
HRP20020071B1 (en) Pharmaceutical composition and preparation thereof
PL323624A1 (en) Novel purgative compositions and methods of manufacturing them
MX9100974A (es) Enzima fibrinolitica hibrida y procedimiento para su preparacion.
NZ512366A (en) Improved methods for processing activated protein C, a lyophilized pharmaceutical formulation containing activated protein C

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU